A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Latest Information Update: 03 Mar 2026
At a glance
- Drugs MORF 057 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms EMERALD-3
- Sponsors Eli Lilly and Company
Most Recent Events
- 23 Feb 2026 New trial record